Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.45 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200745 | 1.00 | MAPT (0.54) | MAPTTHRBALDH1A1LMNAKMT2A | |
| SCHEMBL5264680 | 0.90 | ALDH1A1 (0.54) | MAPTTHRBALDH1A1LMNAKMT2A | |
| SCHEMBL5264676 | 0.90 | ALDH1A1 (0.54) | MAPTTHRBALDH1A1LMNAKMT2A | |
| SCHEMBL7815260 | 0.87 | ALDH1A1 (0.49) | MAPTTHRBALDH1A1LMNAKMT2A | |
| SCHEMBL5232224 | 0.85 | ALDH1A1 (0.51) | MAPTTHRBALDH1A1LMNAKMT2A | |
| SCHEMBL4287745 | 0.85 | ALDH1A1 (0.51) | MAPTTHRBALDH1A1LMNAKMT2A | |
| SCHEMBL4287750 | 0.85 | ALDH1A1 (0.51) | MAPTTHRBALDH1A1LMNAKMT2A | |
| SCHEMBL31219759 | 0.84 | ALDH1A1 (0.48) | MAPTALDH1A1HTTSMN1; SMN2MTNR1A | |
| SCHEMBL7852754 | 0.83 | ALDH1A1 (0.48) | MAPTTHRBALDH1A1LMNAKMT2A | |
| SCHEMBL7852751 | 0.83 | ALDH1A1 (0.48) | MAPTTHRBALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1748999-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005075461-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | MAPT 3632/4885THRB 3973/4885ALDH1A1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.